- Home
- SVRA vs DAWN Comparison
SVRA vs DAWN Comparison
Compare SVRA & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- DAWN
- Stock Information
- Founded
- SVRA 2007
- DAWN 2018
- Country
- SVRA United States
- DAWN United States
- Employees
- SVRA N/A
- DAWN N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- DAWN Health Care
- Exchange
- SVRA Nasdaq
- DAWN Nasdaq
- Market Cap
- SVRA 527.2M
- DAWN 624.8M
- IPO Year
- SVRA N/A
- DAWN 2021
- Fundamental
- Price
- SVRA $3.61
- DAWN $7.18
- Analyst Decision
- SVRA Buy
- DAWN Strong Buy
- Analyst Count
- SVRA 8
- DAWN 7
- Target Price
- SVRA $6.63
- DAWN $27.86
- AVG Volume (30 Days)
- SVRA 1.7M
- DAWN 999.9K
- Earning Date
- SVRA 11-11-2025
- DAWN 10-29-2025
- Dividend Yield
- SVRA N/A
- DAWN N/A
- EPS Growth
- SVRA N/A
- DAWN N/A
- EPS
- SVRA N/A
- DAWN N/A
- Revenue
- SVRA N/A
- DAWN $187,638,000.00
- Revenue This Year
- SVRA N/A
- DAWN $12.56
- Revenue Next Year
- SVRA N/A
- DAWN $48.02
- P/E Ratio
- SVRA N/A
- DAWN N/A
- Revenue Growth
- SVRA N/A
- DAWN 2190.50
- 52 Week Low
- SVRA $1.89
- DAWN $5.64
- 52 Week High
- SVRA $4.70
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- SVRA 65.57
- DAWN 51.39
- Support Level
- SVRA $3.70
- DAWN $7.03
- Resistance Level
- SVRA $3.92
- DAWN $7.58
- Average True Range (ATR)
- SVRA 0.19
- DAWN 0.28
- MACD
- SVRA -0.01
- DAWN -0.04
- Stochastic Oscillator
- SVRA 59.10
- DAWN 30.80
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.